JPWO2023006893A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2023006893A5 JPWO2023006893A5 JP2024505546A JP2024505546A JPWO2023006893A5 JP WO2023006893 A5 JPWO2023006893 A5 JP WO2023006893A5 JP 2024505546 A JP2024505546 A JP 2024505546A JP 2024505546 A JP2024505546 A JP 2024505546A JP WO2023006893 A5 JPWO2023006893 A5 JP WO2023006893A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- pharmaceutical composition
- pharma
- compound
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025023227A JP7836437B2 (ja) | 2021-07-30 | 2025-02-17 | 疼痛、特に神経障害性疼痛、並びに／又は、ａｔ２ｒ及び／若しくはａｔ２ｒ媒介性シグナル伝達に関連する他の疾患若しくは障害の治療のための化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163227552P | 2021-07-30 | 2021-07-30 | |
| US202163227555P | 2021-07-30 | 2021-07-30 | |
| US63/227,552 | 2021-07-30 | ||
| US63/227,555 | 2021-07-30 | ||
| PCT/EP2022/071231 WO2023006893A1 (en) | 2021-07-30 | 2022-07-28 | Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025023227A Division JP7836437B2 (ja) | 2021-07-30 | 2025-02-17 | 疼痛、特に神経障害性疼痛、並びに／又は、ａｔ２ｒ及び／若しくはａｔ２ｒ媒介性シグナル伝達に関連する他の疾患若しくは障害の治療のための化合物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2024528127A JP2024528127A (ja) | 2024-07-26 |
| JPWO2023006893A5 true JPWO2023006893A5 (https=) | 2025-01-17 |
| JP2024528127A5 JP2024528127A5 (https=) | 2025-01-17 |
| JP7637827B2 JP7637827B2 (ja) | 2025-02-28 |
Family
ID=83149285
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024505546A Active JP7637827B2 (ja) | 2021-07-30 | 2022-07-28 | 疼痛、特に神経障害性疼痛、並びに／又は、ａｔ２ｒ及び／若しくはａｔ２ｒ媒介性シグナル伝達に関連する他の疾患若しくは障害の治療のための化合物 |
| JP2025023227A Active JP7836437B2 (ja) | 2021-07-30 | 2025-02-17 | 疼痛、特に神経障害性疼痛、並びに／又は、ａｔ２ｒ及び／若しくはａｔ２ｒ媒介性シグナル伝達に関連する他の疾患若しくは障害の治療のための化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025023227A Active JP7836437B2 (ja) | 2021-07-30 | 2025-02-17 | 疼痛、特に神経障害性疼痛、並びに／又は、ａｔ２ｒ及び／若しくはａｔ２ｒ媒介性シグナル伝達に関連する他の疾患若しくは障害の治療のための化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240368133A1 (https=) |
| EP (1) | EP4377307A1 (https=) |
| JP (2) | JP7637827B2 (https=) |
| KR (1) | KR20240063881A (https=) |
| AU (2) | AU2022318349B2 (https=) |
| CA (1) | CA3227194A1 (https=) |
| CL (1) | CL2024000230A1 (https=) |
| CO (1) | CO2024000880A2 (https=) |
| CR (1) | CR20240041A (https=) |
| DO (1) | DOP2024000017A (https=) |
| EC (1) | ECSP24007288A (https=) |
| IL (1) | IL310330A (https=) |
| JO (1) | JOP20240019A1 (https=) |
| MX (1) | MX2024001155A (https=) |
| PE (1) | PE20241304A1 (https=) |
| WO (1) | WO2023006893A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023006893A1 (en) * | 2021-07-30 | 2023-02-02 | Confo Therapeutics N.V. | Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling |
| CA3254395A1 (en) | 2022-05-17 | 2023-11-23 | Eli Lilly And Company | AT2R'S ANTAGONISTS AND THEIR USES |
| WO2024199402A1 (zh) * | 2023-03-29 | 2024-10-03 | 武汉人福创新药物研发中心有限公司 | 一种作为at2r拮抗剂的杂环化合物 |
| TW202502346A (zh) * | 2023-06-16 | 2025-01-16 | 大陸商武漢人福創新藥物研發中心有限公司 | 作為at2r拮抗劑的雜環化合物及其用途 |
| TW202515864A (zh) * | 2023-10-10 | 2025-04-16 | 大陸商武漢人福創新藥物研發中心有限公司 | 一種at2r拮抗劑及其用途 |
| WO2025180473A1 (zh) * | 2024-02-29 | 2025-09-04 | 上海汇伦医药股份有限公司 | 含四唑类化合物、其药物组合物及其用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU183178B (en) * | 1979-07-13 | 1984-04-28 | Thomae Gmbh Dr K | Process for preparing new carboxylic acid derivatives |
| JPH07509464A (ja) * | 1992-07-17 | 1995-10-19 | メルク エンド カンパニー インコーポレーテッド | 置換ビフェニルメチルイミダゾピリジン |
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| JPH09208570A (ja) * | 1995-07-10 | 1997-08-12 | Senju Pharmaceut Co Ltd | ベンジルピペラジン誘導体 |
| CA2180190A1 (en) * | 1995-07-10 | 1997-01-11 | Kazumi Ogata | Benzylpiperazine derivatives |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| US6124128A (en) | 1996-08-16 | 2000-09-26 | The Regents Of The University Of California | Long wavelength engineered fluorescent proteins |
| ES2125206B1 (es) | 1997-07-21 | 1999-11-16 | Esteve Labor Dr | Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos. |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| WO1999054305A1 (de) | 1998-04-20 | 1999-10-28 | Basf Aktiengesellschaft | Heterocyclisch substituierte amide als calpainhemmer |
| ES2165274B1 (es) | 1999-06-04 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de indolilpiperidina como agentes antihistaminicos y antialergicos. |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| MXPA05010945A (es) | 2003-04-09 | 2005-11-25 | Japan Tobacco Inc | Compuesto pentaciclico heteroaromatico y uso medicinal del mismo. |
| PT1830869E (pt) | 2004-12-24 | 2013-08-22 | Spinifex Pharm Pty Ltd | Método de tratamento ou profilaxia |
| BRPI0614692A2 (pt) | 2005-07-29 | 2009-05-19 | Hoffmann La Roche | derivados de indol-3-il-carbonil-piperidina e piperazina |
| RS54834B1 (sr) | 2010-09-07 | 2016-10-31 | Astellas Pharma Inc | Jedinjenja pirazolokvinolina |
| JP2012171868A (ja) | 2011-02-17 | 2012-09-10 | Tsutomu Takeuchi | Ｎ−ヘテロアリールピペラジン誘導体を有効成分とするｂａｆｆの結合阻害剤 |
| RS58768B1 (sr) | 2013-03-14 | 2019-06-28 | Merck Patent Gmbh | Inhibitori glikozidaze |
| NZ630908A (en) | 2013-07-08 | 2017-08-25 | Novartis Ag | Heterocyclic compounds and methods of their use |
| RU2743074C2 (ru) * | 2014-08-01 | 2021-02-15 | Нуэволюшон А/С | Соединения, активные по отношению к бромодоменам |
| US20180057505A1 (en) | 2015-03-20 | 2018-03-01 | Vertex Pharmaceuticals Incorporated | Bicyclic heteroaryl compounds useful as inhibitors of the par-2 signaling pathway |
| BR112018067775B1 (pt) | 2016-03-04 | 2024-02-15 | Vanderbilt University | Compostos inibidores de mcl-1 indol substituídos, composição farmacêutica compreendendo ditos compostos e usos terapêuticos dos mesmos |
| AR108906A1 (es) * | 2016-06-29 | 2018-10-10 | Bristol Myers Squibb Co | Heterociclos de biarilmetilo |
| WO2018057588A1 (en) | 2016-09-21 | 2018-03-29 | Vertex Pharmaceuticals Incorporated | Furo[3,2-b]pyridine compounds useful as inhibitors of the par-2 signaling pathway |
| AU2019236882B2 (en) | 2018-03-23 | 2023-08-10 | Beijing Tide Pharmaceutical Co., Ltd. | Receptor inhibitor, pharmaceutical composition comprising same, and use thereof |
| KR20210097734A (ko) | 2018-11-28 | 2021-08-09 | 하. 룬드벡 아크티에셀스카브 | Magl 저해제에 의해 질병을 치료하는 방법 |
| WO2023006893A1 (en) * | 2021-07-30 | 2023-02-02 | Confo Therapeutics N.V. | Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling |
-
2022
- 2022-07-28 WO PCT/EP2022/071231 patent/WO2023006893A1/en not_active Ceased
- 2022-07-28 US US18/293,160 patent/US20240368133A1/en active Pending
- 2022-07-28 MX MX2024001155A patent/MX2024001155A/es unknown
- 2022-07-28 KR KR1020247006999A patent/KR20240063881A/ko active Pending
- 2022-07-28 PE PE2024000173A patent/PE20241304A1/es unknown
- 2022-07-28 CA CA3227194A patent/CA3227194A1/en active Pending
- 2022-07-28 EP EP22761413.8A patent/EP4377307A1/en active Pending
- 2022-07-28 AU AU2022318349A patent/AU2022318349B2/en active Active
- 2022-07-28 CR CR20240041A patent/CR20240041A/es unknown
- 2022-07-28 IL IL310330A patent/IL310330A/en unknown
- 2022-07-28 JP JP2024505546A patent/JP7637827B2/ja active Active
-
2024
- 2024-01-24 DO DO2024000017A patent/DOP2024000017A/es unknown
- 2024-01-25 CL CL2024000230A patent/CL2024000230A1/es unknown
- 2024-01-29 EC ECSENADI20247288A patent/ECSP24007288A/es unknown
- 2024-01-30 JO JOJO/P/2024/0019A patent/JOP20240019A1/ar unknown
- 2024-01-30 CO CONC2024/0000880A patent/CO2024000880A2/es unknown
-
2025
- 2025-02-17 JP JP2025023227A patent/JP7836437B2/ja active Active
- 2025-11-25 AU AU2025271263A patent/AU2025271263A1/en active Pending